Risk of prostate cancer death in long-Term users of warfarin: A population-based case-control study

Cancer Causes and Control

Volumn 24, Issue 6, 2013, Pages 1079-1085

  Tagalakis, V ^a   Tamim, H ^b   Blostein, M ^c   Hanley, J A ^d   Kahn, S R ^a  

^a MCGILL UNIVERSITY   (Canada)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Mortality; Pharmacoepidemiology; Prostate cancer; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGE; AGED; ARTICLE; CANADA; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CHRONIC DISEASE SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG USE; FOLLOW UP; HUMAN; LONG TERM EXPOSURE; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROSTATIC NEOPLASMS; RISK FACTORS; SASKATCHEWAN; WARFARIN;

EID: 84892832179     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0185-1     Document Type: Article

References (39)

1. Piccoli A, Lensing AW, Prins MH et al (2004) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2(6):884-889
2. Hejna M, Raderer M, Zielinski CC (1999) Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91:22-36
3. Bobek V, Kovarik J (2004) Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 58:213-219
4. Smorenburg SM, Van Noorden CJ (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93-105
5. Dvorak HF (1986) Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650-1659
6. Francis JL, Biggerstaff J, Amirkhosravi A (1998) Hemostasis and malignancy. Semin Thromb Hemost 24:93-109
7. Levine MN, Lee AY, Kakkar AK (2003) From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 1:1456-1463
8. Tagalakis V, Tamim H, Blostein M, Collet JP, Hanley JA, Kahn SR (2007) Use of warfarin and risk of urogenital cancer: a populationbased, nested case-control study. Lancet Oncol 8:395-402
9. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 342:1953-1958
10. Agostino D, Cliffton EE, Girolami A (1966) Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat. Cancer 19:284-288
11. Brown JM (1973) A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res 33:1217-1224
12. Ryan JJ, Ketcham AS, Wexler H (1968) Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases. Science 162:1493-1494
13. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J (2000) Health databases in Saskatchewan. In: Strom BL (ed) Pharmacoepidemiology, 3rd edn. Wiley, Chichester, pp 325-345
14. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (2000) International classification of diseases for oncology (ICD-0-3), 3rd edn. World Health Organization, Geneva
15. Stratospheric ozone and human health project. Saskatchewan Cancer Registry. Socioeconomic Data Applications Center's (SEDAC). http://sedac.ciesin. columbia.edu/ozone/regs/saskatchewan.html. Accessed 14 May 2012
16. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
17. Rawson NS, Robson DL (2000) Concordance on the recording of cancer in the Saskatchewan Cancer Agency Registry, hospital charts and death registrations. Can J Public Health 91:390-393
18. Jewett HJ (1975) The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2:105-124
19. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP (2001) Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166:2185-2188
20. Von Korff M, Wagner EH, Saunders K (1992) A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203
21. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR (2007) The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 33:358-368
22. Zacharski LR, Henderson WG, Rickles FR et al (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53:2046-2052
23. Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL, Green MR (1989) A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7:993-1002
24. Daly L (1991) The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Meta 9:3-11
25. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P (1994) Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889
26. Maurer LH, Herndon JE 2nd, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a cancer and leukemia group B study. J Clin Oncol 15:3378-3387
27. Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Terrenato I, Sperati F, Schünemann H (2011) Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 6:CD006466
28. Opatrny L, Delaney JA, Tagalakis V, Kahn SR, Suissa S (2007) Warfarin use and the decreased risk of prostate cancer (#PM- 529). Poster presentation at the XXIst congress of the international society of thrombosis and haemostasis. Geneva
29. Pengo V, Noventa F, Denas G, Pengo MF, Gallo U, Grion AM, Iliceto S, Prandoni P (2011) Long-Term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood 117:1707-1709
30. Agnelli G, Verso M (2011) Management of venous thromboembolism in patients with cancer. J Thromb Haemost 9(Suppl. 1):313-324
31. Soørensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850
32. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-634
33. Bobek V, Kovarik J (2004) Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 58(4):213-219
34. International Statistical Classification of Diseases and Related Health Problems (1992-1994) Tenth revision, vol 1-3. World Health Organization, Geneva
35. Kokotailo RA, Hill MD (2005) Coding of stroke and stroke risk factors using International Classification of Diseases, Revisions 9 and 10. Stroke 36:1776-1781
36. Statistics Canada (2005) Comparability of ICD-10 and ICD-9 for mortality statistics in Canada. Ministry responsible for Statistics Canada, Ottawa, pp 5-7
37. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW (2012) Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomized controlled trials. Lancet 379:1602-1612
38. Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R (2012) Low-dose aspirin and cancer mortality: a meta-Analysis of randomized trials. Am J Med 125:560-567
39. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity score to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154:854-864